Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda.
Jillian L KadotaAllan MusinguziHélène E AschmannLydia AkelloFred WelisheJane NakimuliChristopher Allen BergerNoah KiwanukaPatrick Peter John PhillipsAchilles KatambaDavid W DowdyAdithya CattamanchiFred Collins SemitalaPublished in: medRxiv : the preprint server for health sciences (2024)
3HP is being rolled out for TB prevention in high burden countries. We describe the incidence and clinical management of adverse events in a real-world clinical setting among people living with HIV participating in a pragmatic implementation study in Uganda.